2011
DOI: 10.1111/j.1600-0609.2011.01721.x
|View full text |Cite
|
Sign up to set email alerts
|

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*

Abstract: Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related bone disease. Recently, the MRC Myeloma IX trial demonstrated for the first time improved survival and delayed disease progression with the use of an intravenous amino-bisphosphonate, zoledronic acid, vs. an oral agent, clodronate, with intensive and non-intensive anti-myeloma treatment regi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 41 publications
0
5
0
Order By: Relevance
“…Currently, a lot of attention is given to the optimal dosing and duration of treatment in both MM and BC patients. (6,10,(12)(13)(14)49,50) Although our study is small, we find that our data suggest attention should be given to the fact that a substantial fraction of patients still develop skeletal-related events or fractures despite long-term treatment with BP. More investigations are needed to find the reason for this insufficient effect of BP at a few local sites, and more awareness should be created that such local insufficiencies may not be detected if bone resorption markers are not measured frequently.…”
Section: Discussionmentioning
confidence: 70%
See 1 more Smart Citation
“…Currently, a lot of attention is given to the optimal dosing and duration of treatment in both MM and BC patients. (6,10,(12)(13)(14)49,50) Although our study is small, we find that our data suggest attention should be given to the fact that a substantial fraction of patients still develop skeletal-related events or fractures despite long-term treatment with BP. More investigations are needed to find the reason for this insufficient effect of BP at a few local sites, and more awareness should be created that such local insufficiencies may not be detected if bone resorption markers are not measured frequently.…”
Section: Discussionmentioning
confidence: 70%
“…Currently, a lot of attention is given to the optimal dosing and duration of treatment in both MM and BC patients . Although our study is small, we find that our data suggest attention should be given to the fact that a substantial fraction of patients still develop skeletal‐related events or fractures despite long‐term treatment with BP.…”
Section: Discussionmentioning
confidence: 80%
“…The incidence rate of MM worldwide is estimated to be 21 per 1,000,000, and ∼150,000 individuals are newly diagnosed every year worldwide [2] , [3] . The mortality of MM accounts for 1 % of all cancer-related deaths and an estimated 72,000 people die from MM annually [4] .…”
Section: The Disease Burden Of Multiple Myelomamentioning
confidence: 99%
“…Maintenance is advised for patients who have not reached CR. In these cases, one of the new drugs (thalidomide, lenalidomide or bortezomib) is the drug of choice [10].…”
Section: Consequences Of MM Being a Disease Of The Elderlymentioning
confidence: 99%